Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

National Institutes of Health · PAR-25-175 · Deadline: January 7, 2028 · Advertised ceiling: $500k

Opportunity-exact history — these numbers describe this specific funding opportunity (PAR-25-175), from NIH RePORTER.

Awards under this opportunity 1

to 1 distinct organizations. By FY: 2026: 1

Actual award size $668k median

range $668k – $668k

Listing summary

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Education, Health · official listing ↗

This is the free preview

The full brief adds winner tables, recipient breakdowns, the printable "prepared for your client" version, and CSV export — plus a matched-grants list for your client's profile. Client Packet $79 or Pro subscription →

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.